Dare Bioscience, Inc. (DARE) AI Dilution Summary

DARE is funding itself through equity sales: estimated cash was $14,556,178 as of 2026-08-17, from $12,617,594 at 2026-06-30, against estimated monthly burn of $2,258,349. The most recent raise was $5,999,996.58 gross in a registered direct offering closed 2026-08-17. Dilution is driven primarily by the active ATM program with Stifel, Nicolaus & Company, Incorporated, authorised to $18,089,630; because capacity is stated in dollars, a fixed amount issues more shares at a lower price.